Published in Cell Mol Biol (Noisy-le-grand) on November 01, 2004
Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. J Lipid Res (2011) 1.08
Date fruit extract is a neuroprotective agent in diabetic peripheral neuropathy in streptozotocin-induced diabetic rats: a multimodal analysis. Oxid Med Cell Longev (2011) 0.89
Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy? J Diabetes Res (2017) 0.87
Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic neuropathy. Inflammopharmacology (2016) 0.75
Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care (1999) 3.05
Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes (Lond) (2011) 2.39
[Inflammatory rheumatism flare-up after surgical treatment of Cushing's disease: two cases]. Rev Med Interne (1993) 1.51
The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism (1982) 1.46
The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care (1996) 1.41
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia (1991) 1.41
[Post-acute long stay and extensive rehabilitation: study of the first year of work at a long stay university hospital unit]. Ann Ital Med Int (2001) 1.40
Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost (1989) 1.38
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism (1986) 1.30
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab (2005) 1.30
Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment. Eye (Lond) (2005) 1.29
Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation (1997) 1.21
Interference of dapsone in HbA1c monitoring of a diabetic patient with polychondritis. Diabetes Metab (2002) 1.17
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med (1999) 1.12
The Medi-RIVAGE study (Mediterranean Diet, Cardiovascular Risks and Gene Polymorphisms): rationale, recruitment, design, dietary intervention and baseline characteristics of participants. Public Health Nutr (2004) 1.12
Abnormalities of erythrocyte deformability and platelet aggregation in insulin-dependent diabetics corrected by insulin in vivo and in vitro. Lancet (1982) 1.08
Insulin-induced lipoatrophy in type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Diabetes Care (1996) 1.05
Ouabain binding sites and (Na+,K+)-ATPase activity in rat cardiac hypertrophy. Expression of the neonatal forms. J Biol Chem (1986) 1.01
Observations on the critical micellar concentration of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and a series of its homologs and analogs. Chem Phys Lipids (1984) 1.00
Hydrolysis of mixed monomolecular films of triglyceride/lecithin by pancreatic lipase. J Biol Chem (1979) 0.99
Two Na,K-ATPase isoenzymes in canine cardiac myocytes. Molecular basis of inotropic and toxic effects of digitalis. J Biol Chem (1987) 0.97
Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab (1987) 0.96
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis (1989) 0.96
Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) (2000) 0.96
C-peptide replacement improves weight gain and renal function in diabetic rats. Diabetes Metab (2006) 0.95
Molecular cloning of a human gastric lipase and expression of the enzyme in yeast. Biochim Biophys Acta (1987) 0.94
C-peptide, Na+,K(+)-ATPase, and diabetes. Exp Diabesity Res (2004) 0.94
Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin (2010) 0.93
Kinetic assay of human gastric lipase on short- and long-chain triacylglycerol emulsions. Gastroenterology (1986) 0.93
Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisol. Thromb Haemost (1985) 0.91
Alternatives routes of insulin delivery. Diabetes Metab (2006) 0.91
A new kinetic approach for studying phospholipase C (Clostridium perfringens alpha toxin) activity on phospholipid monolayers. Biochemistry (1988) 0.91
Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. Arterioscler Thromb Vasc Biol (2001) 0.91
Novel intestinal phospholipase A2: purification and some molecular characteristics. Biochemistry (1982) 0.91
Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med (1996) 0.91
Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. Arch Biochem Biophys (1983) 0.91
Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care (1998) 0.90
Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats. J Nutr (1999) 0.90
Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab (2011) 0.90
The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. Metabolism (2000) 0.90
Low plasma levels of pancreatic polypeptide in obesity. Diabetes (1980) 0.90
Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost (1999) 0.90
Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes (1990) 0.89
TT virus infection in French hemodialysis patients: study of prevalence and risk factors. J Clin Microbiol (1999) 0.89
Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab (2005) 0.89
Two functional Na+/K(+)-ATPase isoforms in the left ventricle of guinea pig heart. Eur J Biochem (1991) 0.88
Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia (1998) 0.88
Alteration of Na,K-ATPase isoenzymes in diabetic cardiomyopathy: effect of dietary supplementation with fish oil (n-3 fatty acids) in rats. Diabetologia (1997) 0.88
Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev (2000) 0.87
In vivo insulin effect on ATPase activities in erythrocyte membrane from insulin-dependent diabetics. Diabetes (1987) 0.87
Importance of human gastric lipase for intestinal lipolysis: an in vitro study. Biochim Biophys Acta (1986) 0.87
[History, accuracy and precision of SMBG devices]. Diabetes Metab (2003) 0.87
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest (1993) 0.86
Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab (2010) 0.86
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab (2012) 0.86
The increased frequency of the Lewis negative blood group in a diabetic population. Diabetologia (1978) 0.86
Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease. Int J Cardiol (2001) 0.86
Association of diabetic neuropathy with Na/K ATPase gene polymorphism. Diabetologia (1997) 0.86
Intestinal phospholipase, a novel enzyme. J Clin Invest (1982) 0.86
Modulation of mouse cerebral Na+,K(+)-ATPase activity by oxygen free radicals. Neuroreport (1995) 0.86
Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care (1992) 0.85
Paradoxical lessening of autoimmune processes in non-obese diabetic mice after infection with the diabetogenic variant of encephalomyocarditis virus. Eur J Immunol (1990) 0.85
Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord (1998) 0.85
Treatment of diabetes mellitus using an external insulin pump: the state of the art. Diabetes Metab (2008) 0.85
Passive transfer of lymphocytes from diabetic man to athymic mouse. Lancet (1979) 0.85
Obesity and diabetes. Acta Diabetol Lat (1981) 0.84
Determination of portal insulin absorption from peritoneum via novel nonisotopic method. Diabetes (1990) 0.84
Two active Na+/K+-ATPases of high affinity for ouabain in adult rat brain membranes. Biochim Biophys Acta (1990) 0.84
[Neonatal hemoperitoneum: role of ultrasonography. Experience with 4 cases]. Radiol Med (1994) 0.84
[Eosinophilic cell pancreatitis in newborn infants of diabetic mothers]. Ann Anat Pathol (Paris) (1968) 0.84
Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost (1992) 0.83
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. Diabetes Metab (2008) 0.83
Human gastric lipase. The effect of amphiphiles. Eur J Biochem (1986) 0.83
Human gastric lipase: a sulfhydryl enzyme. J Biol Chem (1988) 0.83
Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract (2009) 0.83
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin. Diabetes Obes Metab (2014) 0.83
Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy. Metabolism (1998) 0.83
Hypofibrinolysis and insulin-resistance. Diabete Metab (1991) 0.83
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes (1999) 0.83
Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: a retrospective 35-year study of 12 patients. Diabetes Metab (2008) 0.82
Effect of experimental diabetes on Na/K-ATPase activity in red blood cells, peripheral nerve and kidney. Diabete Metab (1995) 0.82
Assessment of viral and immune factors in EMC virus-induced diabetes: effects of cyclosporin A and interferon. J Clin Lab Immunol (1983) 0.82
A high calorie diet induces type 2 diabetes in the desert sand rat (Psammomys obesus). Cell Mol Biol (Noisy-le-grand) (2007) 0.82
Anti-tubulin antibodies in recent onset type 1 (insulin-dependent) diabetes mellitus: comparison with islet cell antibodies. Diabetologia (1984) 0.82
Stress antecedents and immune status in recently diagnosed type I (insulindependent) diabetes mellitus. Diabete Metab (1989) 0.82
Role of a sulfhydryl group in gastric lipases. A binding study using the monomolecular-film technique. Eur J Biochem (1989) 0.82
Ginkgo biloba extract (EGb 761) protects Na,K-ATPase activity during cerebral ischemia in mice. Neuroreport (1999) 0.81